The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
Abstract
Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2) antagonist with potential antineoplastic activity owing to increase in p53 activity through interruption of the MDM2‐p53 interaction. This phase I, dose‐escalating study assessed the safety, tolerability, efficacy, and pharmacokinetics of milademetan in 18 Japanese patients with solid tumors who relapsed after or were refractory to standard therapy. Patients aged ≥ 20 years received oral milademetan once daily (60 mg, n = 3; 90 mg, n = 11; or 120 mg, n = 4) on days 1 to 21 in a 28‐day cycle. Dose‐limiting toxicities, safety, tolerability, maximum tolerated dose, pharmacokinetics, and recommended dose for phase II were determined. The most frequent treatment‐emergent adverse events included nausea (72.2%), decreased appetite (61.1%), platelet count decreased (61.1%), white blood cell count decreased (50.0%), fatigue (50.0%), and anemia (50.0%). Dose‐limiting toxicities (three events of platelet count decreased and one nausea) were observed in the 120‐mg cohort. The plasma concentrations of milademetan increased in a dose‐dependent manner. Stable disease was observed in seven out of 16 patients (43.8%). Milademetan was well tolerated and showed modest antitumor activity in Japanese patients with solid tumors. The recommended dose for phase II was considered to be 90 mg in the once‐daily 21/28‐day schedule. Future studies would be needed to further evaluate the potential safety, tolerability, and clinical activity of milademetan in patients with solid tumors and lymphomas. The trial was registered with Clinicaltrials.jp: JapicCTI‐142693.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the specific interaction sites are unknown, they all induce cell death in a variety of tumor cells, particularly in patients with MDM2 amplification and intact p53 expression.”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [374]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300
Jeay, S., Ferretti, S., Holzer, P., Fuchs, J., Chapeau, E. A., Wartmann, M., Sterker, D., Romanet, V., Murakami, M., Kerr, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0338 · Cited by 87
Arnhold, V., Schmelz, K., Proba, J., Winkler, A., Wünschel, J., Toedling, J., Deubzer, H. E., Künkele, A., Eggert, A., Schulte, J. H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23409 · Cited by 85
Liao, G., Yang, D., Ma, L., Li, W., Hu, L., Zeng, L., Wu, P., Duan, L., & Liu, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.044 · Cited by 63
Pi, L., Rooprai, J., Allan, D., Atkins, H., Bredeson, C., Fulcher, A., Ito, C., Ramsay, T., Shorr, Stanford, W., et al. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106222 · Cited by 25
Gounder, M. M., Bauer, T. M., Schwartz, G. K., LoRusso, P., Kumar, P., Kato, K., Tao, B., Hong, Y., Patel, P., & Hong, D. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31080-7 · Cited by 19
Research works printed but not linked: 13
- 10.1101/cshperspect.a026104 · DOI · Paper page
- 10.1177/1947601911408889 · DOI · Paper page
- 10.3389/fphar.2020.00631 · DOI
- 10.1126/science.1092472 · DOI · Paper page
- NCBI. National Center for Biotechnology Information.PubChem Compound Summary for CID 73297272 Milademetan. Milademetan.https://pubchem.ncbi.nlm.nih.gov/compound/Milademetan. Accessed Jul. 19 2020.2020.
- 10.1200/JCO.2018.36.15_suppl.11514 · DOI
- 10.1002/sim.3230 · DOI · Paper page
- 10.1016/j.ejca.2008.10.026 · DOI · Paper page
- 10.1038/nrd4288 · DOI
- 10.1186/s13045-017-0500-5 · DOI · Paper page
- 10.1007/s00280-015-2830-8 · DOI
- 10.1038/s41416-018-0355-8 · DOI · Paper page
- 10.1182/bloodadvances.2019030916 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
LoRusso, P., Yamamoto, N., Patel, M. R., Laurie, S. A., Bauer, T. M., Geng, J., Davenport, T., Teufel, M., Li, J., Lahmar, M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0153 · Cited by 101
Self-citationMDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
E3 ubiquitin ligases and their therapeutic potential in disease Management
Madhukar, G., Haque, M. A., Khan, S., Kim, J.-J., & Danishuddin (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116875 · Cited by 26
Metadata
- Authors
- Takahashi, S., Fujiwara, Y., Nakano, K., Shimizu, T., Tomomatsu, J., Koyama, T., Ogura, M., Tachibana, M., Kakurai, Y., Yamashita, T., Sakajiri, S., & Yamamoto, N.
- Affiliations
- The Cancer Institute Hospital of JFCR Tokyo Japan
- Department of Respiratory Medicine Mitsui Memorial Hospital Tokyo Japan
- Department of Experimental Therapeutics National Cancer Center Hospital Tokyo Japan
- Quantitative Clinical Pharmacology Pharmacokinetics Department Daiichi Sankyo Co., Ltd Tokyo Japan
- Data Intelligence Department Daiichi Sankyo Co., Ltd Tokyo Japan
- Oncology Medical Science Department Daiichi Sankyo Co., Ltd Tokyo Japan
- Juntendo Urayasu Hospital Urayasu Japan
- ORCID
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2021-05-02
- Volume
- 112
- Issue
- 6
- Pages
- 2361-2370
- ISSN
- 1347-9032
- 1349-7006
- Cited by
- 50
- References
- 9
- Language
- en
- Funders
- Daiichi Sankyo Company
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. https://app.cochat.ai/papers/10.1111/cas.14875
- The paper
- Takahashi, S., Fujiwara, Y., Nakano, K., Shimizu, T., Tomomatsu, J., Koyama, T., Ogura, M., Tachibana, M., Kakurai, Y., Yamashita, T., Sakajiri, S., & Yamamoto, N. (2021). Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer Science. https://doi.org/10.1111/cas.14875
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.